HBK Investments’s Gilead Sciences GILD Stock Holding History

HBK Investments’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-50,200	Closed	-$4.17M	–	423
2023 Q1	$4.17M	Buy	+50,200	New	+$4.16M	0.03%	107
2021 Q3	–	Sell	-26,600	Closed	-$1.83M	–	799
2021 Q2	$1.83M	Sell	26,600 -11,700	-31%	-$781K	0.01%	512
2021 Q1	$2.48M	Buy	38,300 +10,600	+38%	+$684K	0.01%	446
2020 Q4	$1.61M	Hold	27,700	–	–	0.01%	451
2020 Q3	$1.75M	Hold	27,700	–	–	0.01%	371
2020 Q2	$2.13M	Buy	+27,700	New	+$2.12M	0.03%	295
2018 Q4	–	Sell	-13,500	Closed	-$1.04M	–	1278
2018 Q3	$1.04M	Buy	+13,500	New	+$1.02M	0.01%	707

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HBK Investments's GILD Position: Q2 2021 in Review

HBK Investments sold out of Gilead Sciences (GILD) in Q2 2021, closing a stake of 5,459 shares — an estimated $365K sold.

HBK Investments first reported a position in GILD in Q3 2014 and held it in 22 quarters. The position peaked at $37.1M in Q2 2017. 1,545 funds tracked by Wall St. Rank hold GILD as of Q2 2021.

HBK Investments reported no remaining Gilead Sciences position as of Q2 2021 after selling out during the quarter.
HBK Investments sold 5,459 Gilead Sciences shares in Q2 2021, an estimated $365K.
HBK Investments first reported a position in Gilead Sciences in Q3 2014 and held it in 22 quarters.
HBK Investments's Gilead Sciences position peaked at $37.1M in Q2 2017.
1,545 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2021.

Based on HBK Investments's 13F filing for Q2 2021, filed 16 Aug 2021.